Kim YH, et al. - In dyslipidemic acute myocardial infarction (AMI) patients, major adverse cardiac events (MACE) as well as the incidence of definite or probable stent thrombosis (ST) was compared over a two-year time period following percutaneous coronary intervention (PCI) between those who had durable-polymer (DP)-coated stents (zotarolimus eluting [ZES] and everolimus eluting [EES]) vs those having biodegradable-polymer (BP)-coated biolimus-eluting stent (BES). This study included a total 2,403 patients. The ZES group comprised 953 patients, the EES group 1,145 and the BES group 305. The observations during 2-year follow-up revealed comparable safety and efficacy between ZES, EES, or BES in AMI patients, revealing that they are equally acceptable in dyslipidemic AMI patients during PCI.